Skip to main content

Tiziana Life Sciences Ltd (TLSA)

New York Stock Exchange Healthcare BiotechnologyView data quality →
33.3Poor

ValueMarkers Composite Index

Top 1%#44,247 of 44,707
Overvalued

2454% above intrinsic value ($0)

UndervaluedFair ValueOvervalued
Piotroski
2/9
Weak
Beneish
-
Altman
-16.85
Distress
DCF Value
$0
Overvalued
ROIC
-41.2%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Tiziana Life Sciences Ltd (TLSA) — VMCI valuation read

Tiziana Life Sciences Ltd sits at VMCI 33/100, with the Healthcare sector median at 50. That 17-point spread is the first thing to note on TLSA: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on TLSA are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on TLSA: TLSA trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 2.3x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

TLSA rose 0.4% over the trailing 7 days, with a -16.8% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in TLSA’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.